GU Cancers 2024 | Cardiovascular events in patients with prostate cancer treated with ADT

Benjamin Lowentritt, MD, Chesapeake Urology Research Associates, Baltimore, MD, discusses the incidence of cardiovascular events in patients with prostate cancer treated with androgen deprivation therapy (ADT). Despite clinicians debating about whether to deescalate hormonal therapies, the risk of cardiovascular events in patients is often overlooked. Oncologists need to cooperate with cardiologists to mitigate this risk and raise awareness of this potential issue. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.